US-based medical technology firm Becton, Dickinson and Company (BD) has acquired Venclose for an undisclosed sum.
Established in 2014, Venclose is involved in the development of next-generation solutions for the treatment of chronic venous insufficiency (CVI).
The company has developed a radio frequency (RF) ablation technology platform, which is effective in the treatment of CVI, a disease that results due to malfunctioning valves and may lead to varicose veins.
The acquisition serves as entry point for BD to the treatment of CVI, as well as adds advanced solutions to its existing venous disease portfolio.
BD peripheral intervention worldwide president Paddy O’Brien said: “Our acquisition of Venclose will enable us to offer a more robust portfolio of solutions to physicians who are treating the full range of venous conditions.
“The Venclose RF Ablation System strategically complements our category-leading portfolio of venous disease technologies and aligns with our focus on innovations that provide transformative solutions to improve outcomes for chronic disease and enable the transition into new care settings.”
With one 6 FR sized catheter, the compactly designed Venclose system is available in two heating length sizes, including 2.5cm and 10cm.
The Venclose system, which is said to have 30% more heating length than the longest leading competitive RF ablation catheter, allows physicians to skillfully ablate more vein during each heating cycle.
It also enables to reduce the total number of ablations required for in-vein treatment. The dual heating length catheter helps physicians to ablate both long and short vein segments.
In addition, the system features touchscreen display to deliver real-time procedure data for physicians to take treatment decisions. It also offers audible tones for thermal delivery.
In July this year, BD acquired resorbable polymer technology provider Tepha, which allows the company to drive new innovations in soft tissue repair and regeneration.
